September 3, 2026European Heart Journal
Pre-treatment with P2Y 12 inhibitors in ACS patients: who, when, why, and which agent?
Key result
Review assesses the evidence for P2Y12 inhibitor pretreatment before coronary angiography and PCI.
Why the study?
Recent trials did not fully resolve clinical questions surrounding pre-treatment timing, patient selection, and agent choice across available oral and intravenous P2Y12 inhibitors in ACS.
Does pre-treatment with P2Y12 inhibitors improve outcomes in patients with acute coronary syndrome planned for coronary angiography and possible PCI?
Population
Patients in whom coronary angiography followed by a possible PCI is planned
Comparison
Pre-treatment vs post-angiography treatment with four P2Y12 inhibitors
Design
Clinical review
Authors
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The pretreatment strategy is risky for some patients, including those requiring emergent bypass surgery, as well as for those with aortic dissection or undiscovered bleeding complications.”
Implication
May warrant individualized P2Y12 pre-treatment in ACS; leaves open optimal agent and timing from randomized evidence.
Key Points
- Evaluate available clinical trial evidence regarding the efficacy, timing, and drug selection of P2Y12 inhibitor pre-treatment in acute coronary syndrome patients undergoing coronary angiography.
- Synthesized findings from key prospective and randomized trials, including CREDO, ACCOAST, and ATLANTIC, alongside relevant observational evidence.
- Assessed four oral and intravenous P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor, and cangrelor) across both STEMI and NSTEMI clinical settings.
- Upstream pre-treatment with clopidogrel was historically adopted based on observational data and single-trial trends rather than definitive large-scale randomized trials.
- Dedicated randomized trials evaluating prasugrel in NSTEMI (ACCOAST) and ticagrelor in STEMI (ATLANTIC) failed to resolve all critical questions regarding pre-treatment efficacy and bleeding risks.
- The introduction of the rapid-acting intravenous inhibitor cangrelor introduces new therapeutic pathways that require re-evaluating optimal pre-treatment timing across patient subsets.
Structured PICO
Does pre-treatment with P2Y12 inhibitors improve outcomes in patients with acute coronary syndrome planned for coronary angiography and possible PCI?
P
Population
Patients with acute coronary syndrome (ACS) in whom coronary angiography followed by a possible percutaneous coronary intervention (PCI) is planned.
I
Intervention
Pre-treatment with oral or intravenous P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor, cangrelor) upstream of coronary angiography and PCI.
This review summarizes the evolving evidence on the optimal timing and choice of P2Y12 inhibitor pre-treatment in patients with acute coronary syndrome undergoing angiography.
Cite This Study
Sibbing et al. (2015) conducted a review in Acute coronary syndrome (ACS). Pre-treatment with P2Y12 inhibitors was evaluated. This clinical review evaluates the available evidence regarding pre-treatment with oral and intravenous P2Y12 inhibitors in patients planned for coronary angiography and possible PCI.